Research Article
Multicentre Covariate Adjustment Analysis of Short-Term and 5-Year Outcomes after Endovascular Repair according to Sex
| Characteristic | Females (n = 57) | Males (n = 352) | value |
| Age, years | 76.8 ± 9.5 | 73.5 ± 9.8 | 0.017 | BMI > 30 | 9 (15.8%) | 94 (26.7%) | 0.066 | Ethnicity | | | 0.243 | Caucasian | 52 (92.8%) | 347 (98.6%) | | Asian | — | 4 (1.1%) | | African | — | — | | Maori | — | — | | ATSI | 4 (7.1%) | — | | Others | — | 1 (0.3%) | | Comorbidities | | | | Smoking | | | | Current | 24 (42.11%) | 146 (41.5%) | 0.929 | Former | 13 (22.8%) | 143 (40.9%) | 0.005 | Hypertension | 41 (71.9%) | 269 (76.6%) | 0.447 | Hyperlipidaemia | 28 (50%) | 177 (52.4%) | 0.743 | Diabetes | 12 (21.0%) | 84 (23.9%) | 0.639 | Cardiac | 34 (59.6%) | 177 (50.3%) | 0.188 | Angina | 10 (17.5%) | 60 (17.0%) | 0.926 | Arrhythmia | 8 (14.0%) | 62 (17.6) | 0.496 | CABG | 2 (3.5%) | 40 (11.2%) | 0.042 | CAS | 3 (5.3%) | 24 (6.8%) | 0.652 | CHF | 2 (3.5%) | 27 (7.7%) | 0.215 | MI | 7 (12.5%) | 53 (15.2%) | 0.592 | Renal | 5 (8.8%) | 57 (16.2%) | 0.124 | Carotid | | | | CVA | 7 (12.3%) | 35 (10.0%) | 0.598 | TIA | 5 (8.8%) | 28 (7.9%) | 0.835 | PVD | 13 (22.8%) | 94 (26.7%) | 0.529 | COPD | 14 (24.6%) | 98 (27.8%) | 0.603 | History of malignancy | 6 (10.5%) | 85 (24.1%) | 0.014 | ASA classification | | | 0.445 | Class I | 1 | 3 | | Class II | 12 | 75 | | Class III | 38 | 209 | | Class IV | 6 | 64 | | Stent type | | | 0.764 | 1 Endurant | 22 (38.6%) | 159 (45.4%) | | 2 Cook Zenith | 3 (5.3%) | 28 (8%) | | 3 Gore Excluder | 9 (15.8%) | 56 (16%) | | 4 Nellix®/AFX | 3 (5.3%) | 17 (4.9%) | | 5 Talent | 7 (12.3%) | 33 (9.4%) | | 6 Complex EVAR | 13 (22.8%) | 57 (16.3%) | | Hospital | | | | Public | | | 0.116 |
|
|
Note. BMI: body mass index; ATSI: Aboriginal or Torres Strait Islander; CABG: coronary artery bypass grafting; CAS: coronary artery stenting; CHF: chronic heart failure; MI: myocardial infarction; CVA: cerebrovascular accident; TIA: transient ischaemic attack; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease; ASA: American Society of Anesthesiologists classification; Nellix®: endovascular aneurysm sealing system.
|